Navigation Links
Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
Date:4/23/2012

za's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE™ (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009. In October 2010, the Company received a CRL from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010, a REMS guidance meeting with the FDA in April 2011, and the ADASUVE NDA was resubmitted in August 2011. In December 2011, the ADASUVE NDA was the subject of an advisory committee meeting. In January 2012, Alexza received notice of a 90-day extension of the PDUFA goal date, from February 4, 2012 to May 4, 2012.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A. Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Comp
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Alexza and Grupo Ferrer Amend Adasuve™ Partnership
2. Alexza Announces Proposed Public Offering of Common Stock and Warrants
3. FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexzas ADASUVE™
4. Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference
5. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
6. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
7. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
8. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
9. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
10. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
11. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  BD (Becton, Dickinson and ... technology company, announced today that it will present at the ... Thursday, May 30, 2013, at 10:40 a.m. (ET). ... from the BD corporate website at www.bd.com/investors and ... About BD BD is a ...
(Date:5/24/2013)... China Biologic Products, Inc. (Nasdaq: CBPO, "China Biologic" or ... in China , today announced that ... issued by Shanghai RAAS Blood Products Co., Ltd. ("Shanghai ... that on May 21, 2013, Ms. Siu ... shareholders of the Company, and her spouse, Mr. Tung ...
(Date:5/24/2013)... England and BOSTON , May 24, ... discovery and development company, is pleased to announce that it has ... to augment the Company,s business development capabilities in Japan ... more than 15 years of experience in business development, licensing and ... Sciences, Inc., Roche Pharma ( Japan ), Nippon Roche ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... Scientist to Present Results at 2007 American ... 09, 2007 /PRNewswire-FirstCall/ -- Cleveland,BioLabs, Inc. , ... of,Protectan CBLB502's efficacy as a mitigator of ... damage in non-human primates. The,Company's Chief Scientific ...
... Pa.--(BUSINESS WIRE)--Apr 9, 2007 -,GlaxoSmithKline (LSE and ... from Study 767905/014 and,provided an update on ... 014, a Phase 3, double blind, placebo-controlled ... long-term safety and,tolerability of alvimopan 0.5 mg ...
Cached Medicine Technology:Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 2Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival,Benefits as Mitigator Against Radiation-Induced Damage in Study 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 2GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 3GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 4GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 5GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 6GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg) 7
(Date:5/25/2013)... It's not astonishing that holidays are amongst ... are endless, from family, friends and co-workers. Between the ... more than their parents can afford, parties to arrange, ... graduations, birthdays, anniversaries and it seems like an eternal ... become tired and income can’t catch up to the ...
(Date:5/25/2013)... May 25, 2013 Communities of Distinction ... It is the fifth largest media market in the United ... number one visitor destination in Texas and a major convention ... the American West as it is home to many major ... enjoy from sports to the arts. Residents and locals will ...
(Date:5/25/2013)... -- Animals make great companions for senior citizens, but elderly ... are far more likely to crash than those who never ... study included 2,000 licensed drivers aged 70 and older. The ... they drove with their pet in the car. Among ... was twice as high as among those who never drove ...
(Date:5/25/2013)... St Louis, MO (PRWEB) May 25, 2013 ... goal for the Diet Doc team of weight management professionals. ... weight fast and effectively, Diet Doc’s hCG diets ... uncontrollable factors like abuse during childhood like bullying, more control ... not directly capable of dealing with the underlying factors of ...
(Date:5/25/2013)... May 25, 2013 The latest ... from irritable bowel syndrome (IBS) to bloating, constipation, ... the most long-lasting, embarrassing, frustrating and difficult health ... for digestive health have provided a cure ... many factors contributing to digestive health issues, a ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Seniors More Likely to Crash When Driving With Pet: Study 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2
... initiation of lifesaving antiretroviral therapies should be the standard of ... limited medical and financial resources, according to a study led ... Tutu HIV Centre, University of Cape Town, South Africa. ... Internal Medicine that starting antiretroviral therapy (ART) when the ...
... , LOS ANGELES, July 20 Dr. Chugay, a leading ... patch procedure to aid patients with goals of rapid weight loss. , ... over thir ty years of experience and has personally performed ... surgery expert on The Tonight Show , Entertainment Weekly , CNN ...
... , FLEMINGTON, N.J., July 20 A new national ... (82%) do not believe that drugs containing acetaminophen should be pulled ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO ) , , ... during July 17-19, to obtain physicians, perceptions of a CNN news ...
... , , NEW YORK, ... controversial and thought provoking topics today, MTV,s "16 & Pregnant" season ... (2.1 million) on Thursday, July 16, ranking as the number one ... their favorite series with the "16 & Pregnant: Life After Labor" ...
... working on H1N1 swine flu vaccine, which should be ready ... U.S. Food and Drug Administration has approved the vaccine to ... , The agency noted that this vaccine will not protect ... pandemic proportions around the world and is expected to return ...
... , GREENFIELD, Wis., July 20 ... nutritional service and meal-planning program for cancer patients. The web-based ... . Founded by cancer survivors, the program is based ... It is available to cancer patients and health care systems ...
Cached Medicine News:Health News:Earlier HIV antiviral treatment can be cost effective in areas of limited resources 2Health News:Dr. Chugay (drchugay.com) - Revolutionary Weight Loss Surgery 2Health News:Docs Say No to Pulling Drugs Containing Acetaminophen off the Market 2Health News:Docs Say No to Pulling Drugs Containing Acetaminophen off the Market 3Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 2Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 3Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 4Health News:MTV's Season Finale of '16 & Pregnant' Hit Series Highs Among Both P12-34 (1.9) and Total Viewers (2.1 Million) Thursday, Ranking as the Number One Primetime Cable Program 5Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 2Health News:FDA Approves Seasonal Flu Vaccine for 2009-2010 3Health News:Cancer Survivors Launch New Company, TherapEase Cuisine 2
Anterior chamber protein cell meter. Laser flare meter and cell-counting functions are included in this cell meter, with dramatically enhanced measurement of cell volume....
... new SureSigns VS1 is an ... monitor that provides reliable, accurate, ... VS1 is designed to make ... like large, bright, color-coded LED ...
... High-performance monitoring at the patients side and ... monitors provide essential measurements in a compact ... needs of post-operative care, lower acuity environments, ... strong heritage in patient monitoring, the IntelliVue ...
... Built on Philips strong heritage in ... configuration; an extensive clinical measurements menu; built-in ... EASI* derived 12-lead ECG, and arrhythmia analysis; ... is easy to use and operates on ...
Medicine Products: